Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (S1): 1-8     DOI: 10.3908.ricm15S1S002
Review | Next articles
Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus
Virginia A. Triant
Divisions of Infectious Diseases and General Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Download:  PDF(222KB)  ( 19 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
As a growing number of patients infected with human immunodeficiency virus (HIV) have access to antiretroviral therapy and achieve virologic suppression, the focus of clinical care is shifting from treating the infectious complications of advanced immunodeficiency to managing and preventing chronic disease. The aging of the HIV-positive population and increased rates of chronic disease complications in the setting of HIV infection have increased the impact of noncommunicable diseases such as coronary heart disease (CHD). The effect of HIV on CHD is independent of traditional cardiovascular risk factors and antiretroviral medications and is likely due in part to the chronic inflammation and immune activation underlying HIV infection. This article describes the current state of epidemiologic knowledge on CHD in HIV infection. It highlights key studies in the field and summarizes epidemiologic data with respect to traditional and novel CHD risk factors, specialized clinical subgroups, and broader cardiovascular outcomes.
Key words:  Human immunodeficiency virus      Coronary heart disease      Antiretroviral therapy      Risk factors      Cardiovascular disease      Inflammation     
Published:  20 January 2014     

Cite this article: 

Virginia A. Triant. Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus. Reviews in Cardiovascular Medicine, 2014, 15(S1): 1-8.

URL: 

https://rcm.imrpress.com/EN/10.3908.ricm15S1S002     OR     https://rcm.imrpress.com/EN/Y2014/V15/IS1/1

[1] Adila A Hamid, Amilia Aminuddin, Mohd Heikal Mohd Yunus, Jaya Kumar Murthy, Chua Kien Hui, Azizah Ugusman. Antioxidative and anti-inflammatory activities of Polygonum minus: a review of literature[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 275-287.
[2] Shanna J. Hardin, Mahavir Singh, Wintana Eyob, Jack C. Molnar, Rubens P. Homme, Akash K. George, Suresh C. Tyagi. Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 121-128.
[3] Wenyan Jiang, Mei Wang. New insights into the immunomodulatory role of exosomes in cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 153-160.
[4] Rudaynah A. Alali. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 1-8.
[5] Jing Jin, Yufeng Liu, Lihong Huang, Hong Tan. Advances in epigenetic regulation of vascular aging[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 19-25.
[6] Yun Tian, Pingji Deng, Bing Li, Jieqiong Wang, Ju Li, Yulan Huang, Yan Zheng. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 27-33.
[7] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[8] Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[9] Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
[10] Alberto Palazzuoli, Helen Hashemi, Lauren C. Jameson, Peter A. McCullough. Hyperuricemia and Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 134-145.
[11] Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[12] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[13] Vasiliki Katsi, Manolis S. Kallistratos, Antonios N. Pavlidis, Nikos Karpettas, Ioannis Skoumas, Nikonas Pavleros, Athanasios J. Manolis, Christos Pitsavos, Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros. The Mystery of High-density Lipoprotein: Quantity or Quality? Update on Therapeutic Strategies[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 9-19.
[14] Norman E. Lepor, Dean D. Fouchia, Peter A. McCulloughsup. New Vistas for the Treatment of Obesity: Turning the Tide Against the Leading Cause of Morbidity and Cardiovascular Mortality in the Developed World[J]. Reviews in Cardiovascular Medicine, 2014, 15(S2): 1-21.
[15] Paolo Gresele, Emanuela Falcinelli, Stefania Momi, Daniela Francisci, Franco Baldelli. Highly Active Antiretroviral Therapy–related Mechanisms of Endothelial and Platelet Function Alterations[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 9-20.
No Suggested Reading articles found!